WO2014024210A2 - Nouveaux polymorphes du doxercalciférol - Google Patents

Nouveaux polymorphes du doxercalciférol Download PDF

Info

Publication number
WO2014024210A2
WO2014024210A2 PCT/IN2013/000437 IN2013000437W WO2014024210A2 WO 2014024210 A2 WO2014024210 A2 WO 2014024210A2 IN 2013000437 W IN2013000437 W IN 2013000437W WO 2014024210 A2 WO2014024210 A2 WO 2014024210A2
Authority
WO
WIPO (PCT)
Prior art keywords
doxercalciferol
solid dispersion
pharmaceutically acceptable
solvent
acceptable carrier
Prior art date
Application number
PCT/IN2013/000437
Other languages
English (en)
Other versions
WO2014024210A3 (fr
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Jambula Mukunda Reddy
Bandi Vamsi Krishna
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Publication of WO2014024210A2 publication Critical patent/WO2014024210A2/fr
Publication of WO2014024210A3 publication Critical patent/WO2014024210A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane

Definitions

  • the present invention provides a novel amorphous Form of doxercalciferol, process for its preparation and pharmaceutical compositions comprising it.
  • the present invention also provides a solid dispersion of doxercalciferol in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
  • the present invention further provides a novel crystalline Form of doxercalciferol, process for its preparation and pharmaceutical compositions comprising it.
  • Doxercalciferol is chemically, (lS,3i?,5Z,7£,22£)-9,10-Secoergosta-5,7,10,22- tetraene-l ,3-diol and has the structural formula:
  • Doxercalciferol (trade name Hectorol) is drug for secondary hyperparathyroidism and metabolic bone disease. It is a synthetic analog of ergocalciferol (vitamin D 2 ). It suppresses parathyroid synthesis and secretion. Doxercalciferol and its process were disclosed in U.S. patent no. 3,907,843.
  • Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and/or conformations of the molecules in the crystal Lattice.
  • polymorphs are different crystalline structures of the same pure substance in which the molecules have different arrangements and/or different configurations of the molecules.
  • Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph.
  • Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and infrared spectrometry (IR).
  • XRD X-ray diffraction
  • DSC Differential Scanning Calorimetry
  • IR infrared spectrometry
  • Solvent medium and mode of crystallization play very important role in obtaining one polymorphic Form over the other.
  • Doxercalciferol can exist in different polymorphic Forms, which may differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
  • doxercalciferol a novel amorphous Form of doxercalciferol.
  • the amorphous Form of doxercalciferol is stable, reproducible and so, suitable for pharmaceutical preparations.
  • an object of the present invention is to provide a novel amorphous Form of doxercalciferol, process for its preparation and pharmaceutical compositions comprising it.
  • Another object of the present invention is to provide a solid dispersion of doxercalciferol in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.
  • Another object of the present invention is to provide a novel crystalline Form of doxercalciferol, process for its preparation and pharmaceutical compositions comprising it.
  • the present invention provides a doxercalciferol amorphous Form.
  • the present invention provides a process for the preparation of doxercalciferol amorphous Form, which comprises:
  • the present invention provides a pharmaceutical composition comprising amorphous Form of doxercalciferol and pharmaceutically acceptable excipients.
  • the present invention provides a solid dispersion of doxercalciferol in combination with a pharmaceutically acceptable carrier.
  • the present invention there is provided a process for the preparation of solid dispersion of doxercalciferol in combination with a pharmaceutically acceptable carrier, which comprises:
  • compositions comprising a therapeutically effective amount of solid dispersion of doxercalciferoi along with a pharmaceutically acceptable carrier, and at least one pharmaceutically acceptable excipient.
  • the present invention provides a crystalline Form of doxercalciferoi designated as Form HI characterized by peaks in the powder x-ray diffraction spectrum having 2 ⁇ angle positions at about 3.1, 13.9, 15.8, 16.4 and 16.8 ⁇ 0.2 degrees.
  • the present invention provides a process for the preparation of doxercalciferoi crystalline Form HI , which comprises:
  • step (b) adding water to the solution obtained in step (a);
  • the present invention provides a pharmaceutical composition comprising crystalline Form HI of doxercalciferoi and pharmaceutically acceptable excipients.
  • Figure 1 is an X-ray powder diffraction spectrum of doxercalciferoi amorphous
  • Figure 2 is an X-ray powder diffraction spectrum of solid dispersion of doxercalciferoi in combination with a pharmaceutically acceptable carrier.
  • Figure 3 is an X-ray powder diffraction spectrum of doxercalciferoi crystalline Form HI.
  • X-ray powder diffraction spectrum was measured on a bruker axs D8 advance X- ray powder diffractometer having a copper- ⁇ radiation. Approximately 500 gm of sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two- theta, at 0.020 degrees two theta per step and a step time of 1 second. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 KV and current 35 mA.
  • doxercalciferol amorphous Form The powdered x-ray diffractogram (PXRD) of doxercalciferol amorphous Form is shown in figure 1.
  • a process for the preparation of doxercalciferol amorphous Form which comprises:
  • the alcoholic solvent used in step (a) may preferably be a solvent or mixture of solvents selected from methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, n-butainol and isobutyl alcohol. More preferably the alcoholic solvent is ethanol.
  • Spray drying refers to is a method of producing a dry powder from a liquid or slurry by rapidly drying with a hot gas.
  • a pharmaceutical composition comprising amorphous Form of doxercalciferol and pharmaceutically acceptable excipients, and optionally other therapeutic ingredients.
  • the amorphous Form may preferably be formulated into tablets, capsules, suspensions, dispersions, injectables or other pharmaceutical forms.
  • a solid dispersion of doxercalciferol in combination with a pharmaceutically acceptable carrier is provided.
  • the powdered x-ray diffractogram (PXRD) of solid dispersion of doxercalciferol in combination with a pharmaceutically acceptable carrier is shown in figure 2.
  • Solid dispersion of doxercalciferol in combination with a pharmaceutically acceptable carrier is found to be stable.
  • the solid dispersion of doxercalciferol in combination with a pharmaceutically acceptable carrier may be amorphous.
  • the ratio of doxercalciferol to the pharmaceutically acceptable carrier is 1:0.5 to 1 :4.0.
  • the pharmaceutically acceptable carriers may be one or more of copovidone, ethyl cellulose, povidone, hydroxypropyl methylcellulose, polyethylene glycol, span-20 or soluplus.
  • a process for the preparation of solid dispersion of doxercalciferol in combination with a pharmaceutically acceptable carrier which comprises:
  • Doxercalciferol used in step (a) may preferably be doxercalciferol obtained by the known process.
  • the solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from water, methylene chloride, ethylene chloride, chloroform, carbon tetrachloride, dimethyl sulfoxide, dimethylacetamide, dimethylformamide, methanol, ethanol, isopropanol, n-butanol and n-pentanol. More preferably the solvents are water, methylene chloride, dimethyl sulfoxide, dimethylacetamide, dimethylformamide, ethanol and methanol.
  • the pharmaceutically acceptable carriers used in step (a) may be selected from copovidone, soluplus, povidone or hydroxypropyl methylcellulose.
  • the solvent may be removed from the solution in step (b) by known methods, for example, distillation, freeze drying or spray drying.
  • the distillation of the solvent may be carried out at atmospheric pressure or at reduced pressure.
  • the distillation may preferably be carried out until the solvent is almost completely distilled off.
  • reduced pressure refers to a pressure of less than 100 mmHg.
  • compositions comprising a therapeutically effective amount of solid dispersion of doxercalciferol along with a pharmaceutically acceptable carrier, and at least one pharmaceutically acceptable excipient.
  • the solid dispersion of doxercalciferol may preferably be formulated into tablets, capsules, suspensions, dispersions, injectables or other pharmaceutical forms.
  • a crystalline Form of doxercalciferol designated as Form HI characterized by peaks in the powder x-ray diffraction spectrum having 2 ⁇ angle positions at about 3.1, 13.9, 15.8, 16.4 and 16.8 ⁇ 0.2 degrees.
  • the powdered x-ray diffractogram (PXRD) of doxercalciferol crystalline Form HI is shown in figure 3.
  • a process for the preparation of doxercalciferol crystalline Form HI which comprises:
  • step (b) adding water to the solution obtained in step (a);
  • Doxercalciferol used in step (a) may preferably be doxercalciferol obtained by the known process.
  • the step (c) may conveniently be carried out at room temperature.
  • the doxercalciferol crystalline Form HI may be isolated in step (d) by methods known such as filtration or centrifugation.
  • a pharmaceutical composition comprising crystalline Form HI of doxercalciferol and pharmaceutically acceptable excipients, and optionally other therapeutic ingredients.
  • the crystalline Form HI may preferably be formulated into tablets, capsules, suspensions, dispersions, injectables or other pharmaceutical forms.
  • Doxercalciferol (10 gm) was dissolved in ethanol (100 ml) under stirring and filtered. The resulting filtrate was subjected to spray drying at 85 to 90°C to provide 7.5 gm of doxercalciferol amorphous Form.
  • Doxercalciferol (5 gm) was dissolved in methanol (40 ml) under stirring and filtered. The resulting filtrate was subjected to spray drying at 85 to 90°C to provide 3.5 gm of doxercalciferol amorphous Form.
  • a mixture of doxercalciferol (10 gm) and povidone (10 gm) was dissolved in methanol (300 ml) at room temperature. The contents were heated to 50°C and maintained for 2 hours. The solution was then cooled to room temperature and filtered through celite bed. The solvent was distilled off under reduced pressure at below 55°C and then dried to provide 19.5 gm of doxercalciferol solid dispersion with povidone.
  • a mixture of doxercalciferol (5 gm) and povidone (5 gm) was dissolved in ethanol (100 ml) at room temperature. The contents were heated to 50°C and maintained for 2 hours. The solution was then cooled to room temperature and filtered through celite bed. The solvent was distilled off under reduced pressure at below 55°C and then dried to provide 9 gm of doxercalciferol solid dispersion with povidone.
  • Example 4 was repeated using dimethylformamide solvent instead of methanol solvent to provide doxercalciferol solid dispersion with povidone.
  • Example 4 was repeated using dimethylacetamide solvent instead of methanol solvent to provide doxercalciferol solid dispersion with povidone.
  • Example 4 was repeated using dimethyl sulfoxide solvent instead of methanol solvent to provide doxercalciferol solid dispersion with povidone.
  • Example 4 was repeated using methylene chloride solvent instead of methanol solvent to provide doxercalciferol solid dispersion with povidone.
  • Example 10 was repeated using dimethylformamide solvent instead of methanol solvent to provide doxercalciferol solid dispersion with hydroxypropyl methylcellulose.
  • Example 10 was repeated using dimethylacetamide solvent instead of methanol solvent to provide doxercalciferol solid dispersion with hydroxypropyl methylcellulose.
  • Example 10 was repeated using dimethyl sulfoxide e solvent instead of methanol solvent to provide doxercalciferol solid dispersion with hydroxypropyl methylcellulose.
  • Example 10 was repeated using methylene chloride solvent instead of methanol solvent to provide doxercalciferol solid dispersion with hydroxypropyl methylcellulose.
  • Example 10 was repeated using ethanol solvent instead of methanol solvent to provide doxercalciferol solid dispersion with hydroxypropyl methylcellulose.
  • Example 16 was repeated using ethanol solvent instead of methanol solvent to provide doxercalciferol solid dispersion with hydroxypropyl methylcellulose.
  • Example 16 was repeated using ethanol solvent instead of methanol solvent to provide doxercalciferol solid dispersion with copovidone.
  • Example 18 was repeated using ethanol solvent instead of methanol solvent to provide doxercalciferol solid dispersion with copovidone.
  • Example 16 was repeated using dimethyl formamide solvent instead of methanol solvent to provide doxercalciferol solid dispersion with copovidone.
  • Example 19 was repeated using dimethyl formamide solvent instead of methanol solvent to provide doxercalciferol solid dispersion with copovidone.
  • Example 16 was repeated using dimethylacetamide solvent instead of methanol solvent to provide doxercalciferol solid dispersion with copovidone.
  • Example 20 was repeated using dimethylacetamide solvent instead of methanol solvent to provide doxercalciferol solid dispersion with copovidone.
  • Example 16 was repeated using dimethyl sulfoxide solvent instead of methanol solvent to provide doxercalciferol solid dispersion with copovidone.
  • Example 21 was repeated using dimethyl sulfoxide solvent instead of methanol solvent to provide doxercalciferol solid dispersion with copovidone.
  • Example 16 Preparation of doxercalciferol solid dispersion with copovidone Example 16 was repeated using ethanol solvent instead of methanol solvent to provide doxercalciferol solid dispersion with copovidone.
  • a mixture of doxercalciferol (5 gm) and soluplus (5 gm) was dissolved in methanol (150 ml) at room temperature. The contents were heated to 45 to 50°C and maintained for 2 hours to obtain a clear solution. The solution was then cooled to room temperature and filtered through celite bed. The solvent was distilled off under reduced pressure at below 55°C and then dried to provide 9 gm of doxercalciferol solid dispersion with soluplus.
  • a mixture of doxercalciferol (5 gm) and polyethylene glycol (5 gm) was dissolved in methanol (150 ml) at room temperature. The contents were heated to 45 to 50°C and maintained for 2 hours to obtain a clear solution. The solution was then cooled to room temperature and filtered through celite bed. The solvent was distilled off under reduced pressure at below 55°C and then dried to provide 9 gm of doxercalciferol solid dispersion with polyethylene glycol.
  • Doxercalciferol (10 gm) was dissolved in dimethylformamide (40 ml) under stirring to provide a clear solution. To the solution was added water (400 ml) slowly for 20 minutes and maintained for 6 hours at room temperature. The separated solid was filtered and then dried to provide 9 gm of doxercalciferol crystalline Form HI.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nouvelle forme amorphe du doxercalciférol, son procédé de préparation et compositions pharmaceutiques la contenant. L'invention concerne en outre une dispersion solide de doxercalciférol en combinaison avec un véhicule pharmaceutiquement acceptable, son procédé de préparation et des compositions pharmaceutiques la contenant. Une nouvelle forme cristalline du doxercalciférol, son procédé de préparation et des compositions pharmaceutiques la contenant sont également décrits.
PCT/IN2013/000437 2012-08-10 2013-07-16 Nouveaux polymorphes du doxercalciférol WO2014024210A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3299CH2012 2012-08-10
ININ3299/CHE/2012 2012-08-10

Publications (2)

Publication Number Publication Date
WO2014024210A2 true WO2014024210A2 (fr) 2014-02-13
WO2014024210A3 WO2014024210A3 (fr) 2014-03-27

Family

ID=50068651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000437 WO2014024210A2 (fr) 2012-08-10 2013-07-16 Nouveaux polymorphes du doxercalciférol

Country Status (1)

Country Link
WO (1) WO2014024210A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010039359A1 (en) * 1999-01-20 2001-11-08 Deluca Hector F. Crystalline 1alpha-hydroxyvitamin D2 and method of purification thereof
WO2011098582A2 (fr) * 2010-02-12 2011-08-18 Krka, D.D., Novo Mesto Nouvelles formes de chlorhydrate d'ivabradine
US20110306632A1 (en) * 2010-06-09 2011-12-15 Abbott Laboratories Solid Dispersions Containing Kinase Inhibitors
US20120108554A1 (en) * 2010-10-28 2012-05-03 Formosa Laboratories, Inc. PROCESS FOR PREPARING HIGH PURITY 1alpha-HYDROXY VITAMIN D2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010039359A1 (en) * 1999-01-20 2001-11-08 Deluca Hector F. Crystalline 1alpha-hydroxyvitamin D2 and method of purification thereof
WO2011098582A2 (fr) * 2010-02-12 2011-08-18 Krka, D.D., Novo Mesto Nouvelles formes de chlorhydrate d'ivabradine
US20110306632A1 (en) * 2010-06-09 2011-12-15 Abbott Laboratories Solid Dispersions Containing Kinase Inhibitors
US20120108554A1 (en) * 2010-10-28 2012-05-03 Formosa Laboratories, Inc. PROCESS FOR PREPARING HIGH PURITY 1alpha-HYDROXY VITAMIN D2

Also Published As

Publication number Publication date
WO2014024210A3 (fr) 2014-03-27

Similar Documents

Publication Publication Date Title
EP3122753A2 (fr) Formes solides d'ibrutinib et leur procédé de production
EP2785701B1 (fr) Forme cristalline de carbazitaxel et son procédé de préparation
WO2013132511A1 (fr) Nouveau polymorphe de chlorhydrate de lurasidone
WO2013168126A1 (fr) Formes cristallines du chlorhydrate de vilazodone et de la base libre de la vilazodone
US9624207B2 (en) Polymorphs of azilsartan medoxomil
WO2010076805A2 (fr) Nouveaux polymorphes de malate de sunitinib
KR20170078710A (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
EP2688649B1 (fr) Forme polymorphe de lénalidomide
CA3098274A1 (fr) Formes polymorphes de bictegravir et son sel de sodium
WO2014009970A2 (fr) Dispersion solide de linagliptine
WO2014195977A2 (fr) Nouveaux polymorphes de vismodegib
WO2020082061A1 (fr) Formes à l'état solide de la voclosporine
EP2714683A2 (fr) Ritonavir amorphe co-précipité
EP2575465A1 (fr) Sels de raltégravir
CN117545755A (zh) 一种Lanifibranor的晶型及其制备方法
WO2014024210A2 (fr) Nouveaux polymorphes du doxercalciférol
US10206874B2 (en) Rufinamide solid dispersion
CA2811912A1 (fr) Nouveaux polymorphes de febuxostat
WO2014013505A2 (fr) Vildagliptine amorphe
AU2017329049A1 (en) Process for the preparation of pure and stable crystalline Raltegravir potassium Form 3
WO2017032705A1 (fr) Forme cristalline d'omarigliptine
WO2011139414A2 (fr) Formes polymorphes de dexlansoprazole
WO2017093789A1 (fr) Formes polymorphes de dimaléate d'afatinib
CA2829186A1 (fr) Forme amorphe d'un melange de lopinavir et de ritonavir
WO2006009549A1 (fr) Nouvelles formes cristallines de compositions de matière comprenant les éléments gallium, azote et oxygène

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13827761

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13827761

Country of ref document: EP

Kind code of ref document: A2